People: Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

1:30am IST
Change (% chg)

$0.04 (+1.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Dier, Mardi 

Ms. Mardi C. Dier is a Director of the company. Ms. Dier has served as Executive Vice President and Chief Financial Officer of Portola Pharmaceuticals since November 2013 after joining the company in August 2006. At Portola, Ms. Dier has overseen the development of the accounting, finance, global supply chain, investor relations, communications, IT and facilities functions, and has led the raising of over $1.25 billion in capital. Previously, she served as Vice President of Investor Relations at Chiron Corporation from 2003 until its acquisition by Novartis Pharmaceuticals in April 2006. Prior to joining Chiron, she served as a Director in the West Coast investment banking practice at Prudential Securities, where she focused on biotechnology and other life sciences companies. Ms. Dier was previously at KPMG LLP in the audit department. She holds a B.S. in biology from Stanford University and an M.B.A. from The Anderson School at the University of California, Los Angeles. In 2013, Ms. Dier was recognized as one of the most influential Bay Area business women by the San Francisco Business Times and was a finalist for its Bay Area CFO of the Year Award. We believe Ms. Dier’s more than 25 years’ financial management experience in the biotechnology industry, as well as her experience as a chief financial officer of a publicly traded company, qualifies her to serve on our Board of Directors.

Basic Compensation

Total Annual Compensation, USD 48,125
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 168,235
Fiscal Year Total, USD 216,360

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --